ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies Ltd. (IPA) has reported a record revenue of $24.5 million for FY 2024, a 19% year-over-year increase, driven by demand for its antibody discovery services and strategic AI investments. The company has made significant technological advances, including the launch of the LENSai API and partnerships aimed at enhancing AI-driven healthcare solutions. Despite a net loss, including a substantial impairment charge, IPA highlights robust growth prospects with an expanded laboratory capacity and advanced AI models.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
